vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and Satellogic Inc. (SATL). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $6.2M, roughly 1.5× Satellogic Inc.). Satellogic Inc. runs the higher net margin — 488.0% vs -60.3%, a 548.3% gap on every dollar of revenue. Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-12.8M).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Satellogic Inc. is an American company specializing in Earth-observation satellites, founded in 2010 by Emiliano Kargieman and Gerardo Richarte.
PLX vs SATL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $6.2M |
| Net Profit | $-5.5M | $30.5M |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | -114.2% |
| Net Margin | -60.3% | 488.0% |
| Revenue YoY | -49.9% | — |
| Net Profit YoY | -184.8% | — |
| EPS (diluted) | $-0.06 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $6.2M | ||
| Q3 25 | $17.9M | $3.6M | ||
| Q2 25 | $15.7M | $4.4M | ||
| Q1 25 | $10.1M | $3.4M | ||
| Q4 24 | $18.2M | — | ||
| Q3 24 | $18.0M | — | ||
| Q2 24 | $13.5M | $3.5M | ||
| Q4 23 | $10.5M | — |
| Q4 25 | $-5.5M | $30.5M | ||
| Q3 25 | $2.4M | $4.0M | ||
| Q2 25 | $164.0K | $-6.7M | ||
| Q1 25 | $-3.6M | $-32.6M | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $-2.2M | $-18.1M | ||
| Q4 23 | $-6.0M | — |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q4 23 | 15.5% | — |
| Q4 25 | -51.1% | -114.2% | ||
| Q3 25 | 11.9% | -222.5% | ||
| Q2 25 | 7.5% | -141.6% | ||
| Q1 25 | -41.0% | -280.9% | ||
| Q4 24 | 39.6% | — | ||
| Q3 24 | 22.2% | — | ||
| Q2 24 | -18.0% | -419.2% | ||
| Q4 23 | -53.5% | — |
| Q4 25 | -60.3% | 488.0% | ||
| Q3 25 | 13.2% | 109.2% | ||
| Q2 25 | 1.0% | -149.8% | ||
| Q1 25 | -35.8% | -961.9% | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | — | ||
| Q2 24 | -16.4% | -517.0% | ||
| Q4 23 | -57.6% | — |
| Q4 25 | $-0.06 | $0.24 | ||
| Q3 25 | $0.03 | $-0.02 | ||
| Q2 25 | $0.00 | $-0.06 | ||
| Q1 25 | $-0.05 | $-0.34 | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | — | ||
| Q2 24 | $-0.03 | $-0.20 | ||
| Q4 23 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $94.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $60.5M |
| Total Assets | $82.3M | $151.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $94.4M | ||
| Q3 25 | $13.6M | $28.3M | ||
| Q2 25 | $17.9M | $32.6M | ||
| Q1 25 | $19.5M | $17.7M | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $23.4M | $25.6M | ||
| Q4 23 | $23.6M | — |
| Q4 25 | $48.2M | $60.5M | ||
| Q3 25 | $52.9M | $-56.9M | ||
| Q2 25 | $49.9M | $-68.1M | ||
| Q1 25 | $45.2M | $-83.1M | ||
| Q4 24 | $43.2M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $28.6M | $19.1M | ||
| Q4 23 | $33.6M | — |
| Q4 25 | $82.3M | $151.3M | ||
| Q3 25 | $82.3M | $70.9M | ||
| Q2 25 | $78.5M | $73.8M | ||
| Q1 25 | $73.9M | $61.4M | ||
| Q4 24 | $73.4M | — | ||
| Q3 24 | $61.6M | — | ||
| Q2 24 | $91.5M | $76.6M | ||
| Q4 23 | $84.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-9.5M |
| Free Cash FlowOCF − Capex | $1.6M | $-12.8M |
| FCF MarginFCF / Revenue | 17.8% | -204.9% |
| Capex IntensityCapex / Revenue | 4.4% | 53.6% |
| Cash ConversionOCF / Net Profit | — | -0.31× |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $-34.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-9.5M | ||
| Q3 25 | $-3.7M | $-8.4M | ||
| Q2 25 | $-5.2M | $-4.3M | ||
| Q1 25 | $-5.1M | $-4.7M | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $-3.6M | — | ||
| Q4 23 | $3.6M | — |
| Q4 25 | $1.6M | $-12.8M | ||
| Q3 25 | $-4.2M | $-9.7M | ||
| Q2 25 | $-5.7M | $-5.1M | ||
| Q1 25 | $-5.4M | $-6.6M | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | — | ||
| Q4 23 | $3.3M | — |
| Q4 25 | 17.8% | -204.9% | ||
| Q3 25 | -23.7% | -267.2% | ||
| Q2 25 | -36.2% | -115.3% | ||
| Q1 25 | -53.0% | -195.9% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | — | ||
| Q4 23 | 31.9% | — |
| Q4 25 | 4.4% | 53.6% | ||
| Q3 25 | 2.8% | 36.8% | ||
| Q2 25 | 2.8% | 17.5% | ||
| Q1 25 | 3.0% | 56.5% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q4 23 | 2.4% | — |
| Q4 25 | — | -0.31× | ||
| Q3 25 | -1.58× | -2.11× | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SATL
| Transferred At Point In Time | $5.7M | 91% |
| Other | $547.0K | 9% |
